Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Acme United Corporation
WARNING LETTER
•Acme United Corporation•March 28, 2025

Acme United Corporation – FDA Warning Letter, Mar 28, 2025

Record Details

The FDA issued a Warning Letter to Acme United Corporation on October 10, 2025, following an inspection from March 18-28, 2025, at their Shelton, CT drug manufacturing facility. The letter outlines significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals (21 CFR parts 210 and 211), rendering their drug products adulterated under the Federal Food, Drug, and Cosmetic Act. The primary issue identified was the company"s failure to adequately design, control, and maintain its water system, which is used in manufacturing topical over-the-counter drug products. Investigators repeatedly found objectionable microorganisms, specifically *Burkholderia cepacia*, and "too numerous to count" results, indicating a recalcitrant biofilm. The firm also failed to conduct timely and comprehensive investigations into these out-of-limit microbiological results, including root cause and product impact assessments. The FDA deemed the company"s response, which cited low safety risk and antimicrobial effects, inadequate, emphasizing that such formulations do not substitute for CGMP. Concerns were also raised about the design of a newly installed on-demand, non-recirculating water system. Acme United Corporation is required to provide a comprehensive assessment and remediation plan for its water system, an independent assessment of the new system, and a robust ongoing control and monitoring program. They must also submit an updated risk assessment for all distributed drug products, an action plan for microbiological testing of retain samples, stability study data, and a summary of all new water system test results. Furthermore, a retrospective review of invalidated out-of-limit water test results and a comprehensive remediation plan for their Out-of-Specification/Out-of-Limit investigation systems are mandated.

Company
Acme United Corporation
Inspection date
March 28, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · f59e6acc-8450-435c-8745-40387d77c227

Violation Codes9
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.6321 CFR 211.19221 CFR 211.100(a)21 CFR 211.113(b)21 CFR 211.167(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Acme United Corporation
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.